Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA

Swedbank AB acquired a new stake in Savara Inc. (NASDAQ:SVRA) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 550,000 shares of the company’s stock, valued at approximately $1,964,000. Swedbank AB owned approximately 0.32% of Savara as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in SVRA. Sivia Capital Partners LLC grew its stake in Savara by 9.1% in the second quarter. Sivia Capital Partners LLC now owns 41,500 shares of the company’s stock valued at $95,000 after acquiring an additional 3,459 shares during the period. BNP Paribas Financial Markets raised its position in shares of Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Savara by 17.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock valued at $87,000 after purchasing an additional 5,687 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Savara by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after purchasing an additional 6,449 shares during the period. Finally, Sio Capital Management LLC grew its position in shares of Savara by 1.0% in the 2nd quarter. Sio Capital Management LLC now owns 726,851 shares of the company’s stock valued at $1,657,000 after purchasing an additional 7,197 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Performance

Shares of SVRA stock opened at $6.45 on Friday. Savara Inc. has a 12 month low of $1.89 and a 12 month high of $7.01. The company’s fifty day simple moving average is $5.23 and its 200-day simple moving average is $3.72. The firm has a market cap of $1.31 billion, a PE ratio of -12.17 and a beta of 0.23. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Equities research analysts expect that Savara Inc. will post -0.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on SVRA shares. Citigroup restated an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. Guggenheim reissued a “buy” rating on shares of Savara in a research report on Tuesday. JMP Securities boosted their price objective on shares of Savara from $8.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, October 23rd. Lifesci Capital raised shares of Savara to a “strong-buy” rating in a research note on Tuesday, October 14th. Finally, HC Wainwright increased their target price on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.13.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.